Literature DB >> 16225763

Alterations of placental cytochrome P450 1A1 and P-glycoprotein in tobacco-induced intrauterine growth retardation in rats.

You-e Yan1, Hui Wang, Ying-hong Feng.   

Abstract

AIM: To investigate the alterations of placental P-glycoprotein (P-gp) and cytochrome P450 1A1 (CYP1A1) at different gestational days (GD), and to explore the possible significance of placental P-gp and CYP1A1 in tobacco smoke-induced intrauterine growth retardation (IUGR) in rats.
METHODS: An IUGR model was produced by passive tobacco smoking from GD7 to parturition (GD21) and predicted using fetal development parameters. Placental structure and function were monitored by observing pathological alteration and antioxidative function, including the content of malondialdehyde and the activities of superoxide dismutase and catalase (CAT). The expressions of CYP1A1 and P-gp (mdr 1a and mdr 1b) were detected using a reverse transcription polymerase chain reaction and immunohistochemistry.
RESULTS: Placental pathological changes occurred and the malondialdehyde content increased, whereas the activities of superoxide dismutase and CAT lowered, when compared to their controls. In the rat placenta of the tobacco group, the level of CYP1A1 mRNA increased significantly; the level of mdr1a mRNA increased significantly at GD21 but not at GD14, whereas the level of mdr1b mRNA in different term remained stable; the expression of P-gp increased significantly only in full-term placenta.
CONCLUSION: The expression of placental CYP1A1 and P-gp increased in tobacco-induced IUGR. Overexpression of placental CYP1A1 can attribute to the metabolism of tobacco and the generation of reactive metabolites, which can trigger IUGR. As a compulsory mechanism, upregulation of P-gp might decrease tobacco exposure to a developing fetus with IUGR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16225763     DOI: 10.1111/j.1745-7254.2005.00209.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  5 in total

1.  Prognostic value of using glucosylceramide synthase and cytochrome P450 family 1 subfamily A1 expression levels for patients with triple-negative breast cancer following neoadjuvant chemotherapy.

Authors:  Jiannan Liu; Shuhua Wang; Congcong Wang; Xiangshuo Kong; Ping Sun
Journal:  Exp Ther Med       Date:  2021-01-22       Impact factor: 2.447

Review 2.  Regulation of Placental Efflux Transporters during Pregnancy Complications.

Authors:  Danielle Kozlosky; Emily Barrett; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2022-01-06       Impact factor: 3.579

3.  H3K9ac of TGFβRI in human umbilical cord: a potential biomarker for evaluating cartilage differentiation and susceptibility to osteoarthritis via a two-step strategy.

Authors:  Yongjian Qi; Bin Li; Yinxian Wen; Xu Yang; Biao Chen; Zheng He; Zhe Zhao; Jacques Magdalou; Hui Wang; Liaobin Chen
Journal:  Stem Cell Res Ther       Date:  2021-03-04       Impact factor: 6.832

4.  Unraveling the Genetic Architecture of Hepatoblastoma Risk: Birth Defects and Increased Burden of Germline Damaging Variants in Gastrointestinal/Renal Cancer Predisposition and DNA Repair Genes.

Authors:  Talita Aguiar; Anne Teixeira; Marília O Scliar; Juliana Sobral de Barros; Renan B Lemes; Silvia Souza; Giovanna Tolezano; Fernanda Santos; Israel Tojal; Monica Cypriano; Silvia Regina Caminada de Toledo; Eugênia Valadares; Raquel Borges Pinto; Osvaldo Afonso Pinto Artigalas; Joaquim Caetano de Aguirre Neto; Estela Novak; Lilian Maria Cristofani; Sofia M Miura Sugayama; Vicente Odone; Isabela Werneck Cunha; Cecilia Maria Lima da Costa; Carla Rosenberg; Ana Krepischi
Journal:  Front Genet       Date:  2022-04-12       Impact factor: 4.772

5.  The effects of β-naphthoflavone on rat placental development.

Authors:  Satoshi Furukawa; Naho Tsuji; Seigo Hayashi; Yusuke Kuroda; Masayuki Kimura; Chisato Hayakawa; Kazuya Takeuchi; Akihiko Sugiyama
Journal:  J Toxicol Pathol       Date:  2019-08-20       Impact factor: 1.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.